Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Musculoskeletal Pain 1Lewy Body Disease 1Drug-Related Side Effects and Adverse Reactions 1Congenital Hyperinsulinism 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiotherapy 3Pyridoxine 2Etoposide 2Epoetin Alfa 2Cisplatin 2Capecitabine 2uridine triacetate 1peginterferon alfa-2b 1pegaspargase 1Vincristine 1Pyridostigmine Bromide 1Prednisolone 1Paclitaxel 1Oxaliplatin 1Octreotide 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Laparoscopy 1Introns 1Hydrocortisone 1Gemcitabine 1Furosemide 1Fluorouracil 1Filgrastim 1Erythropoietin 1Duloxetine Hydrochloride 1Doxorubicin 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Drug-Related Side Effects and Adverse Reactions × Furosemide × Clear all
NCT06407401 2024-11-05

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Not yet recruiting
399 enrolled
Breast

Breast Neoplasms, Musculoskeletal Pain, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡